Drug Name Classification Mechanism of Action Indication Contraindication Adverse Reaction Nursing Responsibilities

Generic Name: Pharmacologic: > Causes rapid depolarization It is indicated for: Contraindicated CNS : Before
of membrane potential in
Daptomycin Cyclic following binding to bacterial dizziness > Obtain CPK and blood
hypersensitivity
lipopeptide membrane; this results in > Complicated skin cultures.
to daptomycin.
antibacterial inhibition of protein, DNA, and and skin structure
RNA synthesis.
> Assess renal function
agents infections caused by CV:
history.
Gram-positive
Brand Name: bacteria hypertension,
> Screen for statin use.
Therapeutic Effects: hypotension
Cubicin, Cubicin Precaution:
RF Death of bacteria with
Therapeutic: > Staphylococcus CCr 30 mL/min,
resolution of infection. moderate-to-
aureus bacteremia GI:
Anti-infectives severe renal
(in adults)
impairment, CLOSTRIDIUM
Geriatric patients, DIFFICILE- During
Minimum Dose: Pregnancy, ASSOCIATED
Pharmacokinetics > Staphylococcus > Monitor for myopathy,
Lactation; Children DIARRHEA (CDAD),
4 mg/kg q48h IV aureus bacteremia
Absorption: <18 yr. constipation, CPK levels, and renal
(in pediatric
diarrhea, nausea, function.
Pregnancy IV administration results in patients)
vomiting, increase
Category: complete bioavailability > Assess oral cavity for
liver enzymes
thrush.
Maximum B
Drug Interaction:
Dose: Distribution: > Monitor bowel patterns
Drug-drug: GU: for diarrhea or colitis.
12 mg/kg q24h Unknown
Tobramycin renal failure
QD IV > Observe for signs of
increase blood superinfection
levels. Concurrent
Metabolism: HMG-CoA Hematologic: > Monitor for dizziness.
Availability and reductase
color: Unknown inhibitors may anemia
increase the risk of
Lyophilized myopathy.
powder for Excretion: LOCAL:
injection
(requires Mostly excreted by kidneys injection site
reconstitution): reactions.
350 mg/vial, 500 After
mg/vial. Half life: > Educate patient to report
Skin:
8.1 hr rash, headache, nausea,
DRUG RASH WITH dizziness, constipation,
Route: EOSINOPHILIA AND diarrhea, muscle pain, or
SYSTEMIC any new symptoms.
IV Onset:
SYMPTOMS (DRESS),
Rapid pruritus, rash

Peak: Resp:
End of infusion EOSINOPHILIC
PNEUMONIA,
dyspnea.
Duration:
24 hr Others:

kinase,
ANGIOEDEMA, fever.
Reference:

Vallerand, A. H., & Sanoski, C. A. (2021). Davis's drug guide for nurses. Seventeenth edition. Philadelphia, PA, F.A. Davis Company.

Vallerand, A. H., & Deglin, J. H. (2009). Davis's Drug Guide for Nurses Eleventh Edition - 20th Anniversary Edition. Eleventh edition. Philadelphia,
PA, F.A. Davis Company.

NOTE: The total grading scale for the drug study is 50 points

Grading Rubrics:
● Content/Completeness: 20 points
● Organization: 15 points
● Neatness: 5 points
● Adherence to the format and timely submission: 10 points